Q2 EPS Forecast for Elanco Animal Health Lowered by Analyst

Elanco Animal Health Incorporated (NYSE:ELAN) – William Blair cut their Q2 2025 earnings estimates for shares of Elanco Animal Health in a research report issued on Wednesday, May 7th. William Blair analyst B. Vazquez now expects that the company will earn $0.19 per share for the quarter, down from their prior forecast of $0.22. The consensus estimate for Elanco Animal Health’s current full-year earnings is $0.91 per share. William Blair also issued estimates for Elanco Animal Health’s Q2 2026 earnings at $0.26 EPS.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.06. The firm had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company’s revenue for the quarter was down 1.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.34 earnings per share.

Several other equities analysts have also issued reports on the company. Stifel Nicolaus boosted their price target on Elanco Animal Health from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday. UBS Group decreased their price objective on Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating for the company in a report on Wednesday, February 26th. Morgan Stanley dropped their price target on shares of Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 26th. Piper Sandler decreased their price objective on shares of Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating for the company in a research note on Thursday, March 6th. Finally, Barclays cut their target price on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, Elanco Animal Health has an average rating of “Hold” and an average target price of $15.00.

Elanco Animal Health Stock Down 2.1 %

Shares of NYSE ELAN opened at $12.02 on Friday. Elanco Animal Health has a 52-week low of $8.02 and a 52-week high of $18.80. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. The company’s 50 day moving average price is $9.89 and its 200-day moving average price is $11.43. The company has a market capitalization of $5.97 billion, a P/E ratio of 30.05, a price-to-earnings-growth ratio of 2.50 and a beta of 1.49.

Hedge Funds Weigh In On Elanco Animal Health

Institutional investors and hedge funds have recently bought and sold shares of the stock. Allworth Financial LP boosted its stake in shares of Elanco Animal Health by 791.7% during the first quarter. Allworth Financial LP now owns 2,354 shares of the company’s stock valued at $25,000 after purchasing an additional 2,090 shares during the period. CoreCap Advisors LLC bought a new stake in Elanco Animal Health during the 4th quarter valued at $29,000. Wilmington Savings Fund Society FSB purchased a new stake in Elanco Animal Health during the 3rd quarter valued at $35,000. NBC Securities Inc. bought a new stake in Elanco Animal Health in the 1st quarter worth $40,000. Finally, Parallel Advisors LLC increased its position in shares of Elanco Animal Health by 92.2% in the first quarter. Parallel Advisors LLC now owns 3,860 shares of the company’s stock valued at $41,000 after acquiring an additional 1,852 shares during the period. 97.48% of the stock is currently owned by institutional investors.

Insider Activity at Elanco Animal Health

In related news, Director Lawrence Erik Kurzius acquired 10,000 shares of the firm’s stock in a transaction dated Tuesday, March 11th. The shares were purchased at an average price of $10.20 per share, for a total transaction of $102,000.00. Following the completion of the acquisition, the director now owns 111,459 shares in the company, valued at approximately $1,136,881.80. This represents a 9.86 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. 0.89% of the stock is currently owned by insiders.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.